Physician profile
David D Reed
NPI 1205838422
$3,371.55
in general payments reported to CMS, 2019-2025
22 companies · $877 in 2025
The $877 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $169 · 2021: $334 · 2022: $404 · 2023: $780 · 2024: $562 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $602.03 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $496.28 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $356.98 | 2019-2025 | Cequa |
| Abbvie INC. | $297.12 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $261.41 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $253.97 | 2019-2022 | |
| Alcon Vision LLC | $246.15 | 2021-2025 | Rocklatan, Hydrus Microstent |
| New World Medical,INC. | $147.92 | 2023 | |
| Oyster Point Pharma, INC. | $121.79 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $117.70 | 2019-2022 | |
| Biotissue Holdings INC. | $78.37 | 2019-2024 | |
| Harrow Eye, LLC | $75.37 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $66.82 | 2019-2021 | |
| Rxsight INC | $64.47 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.69 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.64 | 2023 | Iyuzeh |
| Glaukos Corporation | $24.29 | 2023 | |
| Eyepoint US, INC. | $22.03 | 2019 | |
| Dompe US, INC. | $20.12 | 2021 | |
| Shire North American Group INC | $17.21 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $14.22 | 2019 | |
| Sight Sciences, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.